drugset / Trial / NCT03531697

Study of Loteprednol Etabonate in Adults Undergoing Bilateral Cataract Surgery

NCT03531697

Phase 1 Completed 381 enrolled Sandoz
RandomizedCrossoverSingle-blindOther

Summary

This study will assess the bioequivalence of Loteprednol Etabonate and the reference listed drug (RLD)

Timeline

Start
2018-04-26
Primary completion
2019-09-07
Completion
2019-10-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Loteprednol Etabonate Other / unclassified

Indications

No indication recorded.